Paracetamol Codeine Brillpharma (Ireland) (Paracetamol, Codeine Phosphate Hemihydrate)

Paracetamol acts centrally by inhibiting the cyclo‑oxygenase (COX) enzymes that produce prostaglandins, which are mediators of pain and fever. This reversible inhibition reduces the hypothalamic set‑point for temperature and diminishes the perception of pain. In the combination, its effect complements codeine’s opioid‑mediated analgesia, providing a broader spectrum of pain control.

The appropriate dose of Paracetamol Codeine Brillpharma is determined by the prescribing clinician based on the patient’s age, weight, severity of pain, and overall health status. The prescriber will consider existing medical conditions, concomitant medications, and regulatory limits for codeine‑containing products. Patients should follow the exact instructions on the prescription label and not exceed the recommended amount.

Paracetamol is generally considered compatible with pregnancy when used at the lowest effective dose, but codeine crosses the placenta and may affect the fetus, especially in the third trimester. During breastfeeding, codeine can be transferred to breast milk and may cause sedation in the infant. Healthcare providers should evaluate the risk‑benefit ratio and may recommend alternative therapies for pregnant or nursing mothers.

To place an order, visit the product page on gnhindia.com and submit an enquiry with the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, requesting verification of trade or institutional credentials. After review, the sales team will respond with pricing, availability, shipping details—including any temperature controls—and the necessary import documentation.

Compared with single‑ingredient paracetamol, the addition of codeine provides stronger analgesia for moderate pain but introduces opioid‑related risks such as dependence and respiratory depression. Relative to non‑steroidal anti‑inflammatory drugs (NSAIDs), the combination does not cause gastric irritation but may affect liver function and carries opioid‑specific cautions. Choice of therapy depends on pain severity, patient comorbidities, and safety considerations.

Paracetamol Codeine Brillpharma should be stored at room temperature, typically below 25 °C, in its original packaging to protect it from moisture and light. The container should be kept tightly closed and placed out of reach of children. Do not store the product in a bathroom or near heat sources, and discard any tablets that appear discoloured or damaged.

The medication is taken orally, usually as a tablet, with a full glass of water. It may be taken with or without food, although taking it with food can reduce gastrointestinal discomfort. The tablet should be swallowed whole and not crushed or chewed unless specifically instructed by a healthcare professional. Proper administration ensures optimal absorption and therapeutic effect.

The most serious risks include respiratory depression, especially in patients with compromised breathing or when combined with other depressants; severe allergic reactions such as anaphylaxis; hepatotoxicity from excessive paracetamol intake; and the potential for opioid dependence or abuse. Patients should be monitored closely for signs of these events, and any sudden difficulty breathing, rash, or unusual fatigue should prompt immediate medical attention.

Paracetamol Codeine is contraindicated in individuals with known hypersensitivity to paracetamol, codeine, or any excipients, as well as in patients with severe hepatic impairment, significant respiratory depression, or acute asthma attacks. It should also be avoided in children under the age limits set by local regulations for codeine‑containing products, and in patients taking monoamine oxidase inhibitors within 14 days. Consultation with a healthcare provider is essential before use.